Clinical Trial Update: EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing 177Lu-PSMA therapy alone versus 177Lu-PSMA with ipilimumab and nivolumab in men with metastatic castration-resistant pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostatic Neoplasms

Drugs mentioned

• 177Lu-PSMA
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Status: UNKNOWN